|
gptkbp:instanceOf
|
gptkb:drug
antifolate chemotherapy agent
|
|
gptkbp:administeredBy
|
folic acid
intravenous infusion
vitamin B12
|
|
gptkbp:approvedBy
|
gptkb:FDA
2004
|
|
gptkbp:ATCCode
|
L01BA04
|
|
gptkbp:brand
|
gptkb:Alimta
|
|
gptkbp:CASNumber
|
137281-23-3
|
|
gptkbp:category
|
antineoplastic agent
|
|
gptkbp:chemicalFormula
|
C20H21N5O6
|
|
gptkbp:combines
|
gptkb:carboplatin
gptkb:cisplatin
|
|
gptkbp:contraindication
|
severe renal impairment
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:halfLife
|
3.5 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pemetrexed
|
|
gptkbp:KEGGID
|
D08302
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits dihydrofolate reductase
inhibits glycinamide ribonucleotide formyltransferase
inhibits folate-dependent enzymes
inhibits thymidylate synthase
|
|
gptkbp:metabolism
|
minimal hepatic metabolism
|
|
gptkbp:molecularWeight
|
471.41 g/mol
|
|
gptkbp:patent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:patentExpired
|
2016 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
446220
DB00642
|
|
gptkbp:riskFactor
|
myelosuppression
renal toxicity
hepatic toxicity
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
rash
neutropenia
mucositis
|
|
gptkbp:synonym
|
gptkb:pemetrexed_disodium
gptkb:LY231514
|
|
gptkbp:UNII
|
UW440V8KJC
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
malignant pleural mesothelioma
|
|
gptkbp:bfsParent
|
gptkb:Alimta
|
|
gptkbp:bfsLayer
|
6
|